Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Review Article

Mecamylamine (Inversine®): an old antihypertensive with new research directions

Journal of Human Hypertension volume 16, pages 453–457 (2002)Cite this article

Abstract

Mecamylamine (Inversine®), the first orally available antihypertensive agent, is now rarely used. Although celebrated in the 1950s, mecamylamine fell out of favour because of its widespread ganglionic side effects at antihypertensive doses (30–90 mg/day). However, recent studies suggest that mecamylamine is very effective at relatively low doses (2.5–5 mg b.i.d.) for blocking the physiological effects of nicotine and improving abstinence rates in smoking cessation studies, particularly for women. When these lower doses of mecamylamine are given, patients do not experience the severity of side effects that made the drug unpopular for the treatment of hypertension. Tobacco smoking is a strong risk factor for cardiovascular morbidity, including accelerated atherosclerosis and increased risk of heart attacks. Though currently untested, the available evidence suggests that low-dose mecamylamine therapy might reduce blood pressure variability and atherogenetic lipid profile in smokers. With this in mind, mecamylamine should be an important research tool in the field of hypertension research, particularly in recalcitrant smokers with mild to moderate hypertension.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Schuller HM, Jull BA, Sheppard BJ, Plummer HK . Interaction of tobacco-specific toxicants with the neuronal alpha(7) nicotinic acetylcholine receptor and its associated mitogenic signal transduction pathway: potential role in lung carcinogenesis and pediatric lung disorders Eur J Pharmacol 2000; 393: 265–277

    Article  CAS  Google Scholar 

  2. Plummer HK 3rd, Sheppard BJ, Schuller HM . Interaction of tobacco-specific toxicants with nicotinic cholinergic regulation of fetal pulmonary neuroendocrine cells: implications for pediatric lung disease Exp Lung Res 2000; 26: 121–135

    Article  CAS  Google Scholar 

  3. Villablanca AC . Nicotine stimulates DNA synthesis and proliferation in vascular endothelial cells in vitro J Appl Physiol 1998; 84: 2089–2098

    Article  CAS  Google Scholar 

  4. Saareks V et al. Clinical pharmacology of eicosanoids, nicotine induced changes in man J Physiol Pharmacol 2000; 51: 631–642

    CAS  PubMed  Google Scholar 

  5. Stone CA, Torchiana ML, Navarro A, Beyer KH . Ganglionic blocking properties of 3-methylaminoisocamphane hydrochloride (mecamylamine): a secondary amine J Pharmacol 1956; 117: 169–183

    CAS  Google Scholar 

  6. Baer JE, Paulson SF, Russo HF, Beyer KH . Renal elimination of 3-methylaminoisocamphane hydrochloride (mecamylamine) Am J Physiol 1956; 186: 180–186

    Article  CAS  Google Scholar 

  7. Martin BR, Onaivi ES, Martin TJ . What is the nature of mecamylamine's antagonism of the central effects of nicotine? Biochem Pharmacol 1989; 38: 3391–3397

    Article  CAS  Google Scholar 

  8. Young JM, Shytle RD, Sanberg PR, George TP . Mecamylamine: new therapeutic uses and toxicity/risk profile Clin Ther 2001; 23: 532–565

    Article  CAS  Google Scholar 

  9. Papke RL, Sanberg PR, Shytle RD . Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes J Pharmacol Exp Ther 2001; 297: 646–656

    CAS  PubMed  Google Scholar 

  10. Reid MS, Mickalian JD, Delucchi KL, Berger SP . A nicotine antagonist, mecamylamine, reduces cue-induced cocaine craving in cocaine-dependent subjects Neuropsychopharmacology 1999; 20: 297–307

    Article  CAS  Google Scholar 

  11. Blomqvist O, Engel JA, Nissbrandt H, Soderpalm B . The mesolimbic dopamine-activating properties of ethanol are antagonized by mecamylamine Eur J Pharmacol 1993; 249: 207–213

    Article  CAS  Google Scholar 

  12. Rose JE, Sampson A, Levin ED, Henningfield JE . Mecamylamine increases nicotine preference and attenuates nicotine discrimination Pharmacol Biochem Behav 1989; 32: 933–938

    Article  CAS  Google Scholar 

  13. Rose JE et al. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone Clin Pharmacol Therapeut 1994; 56: 86–99

    Article  CAS  Google Scholar 

  14. Rose JE, Behm FM, Westman EC . Nicotine-mecamylamine treatment for smoking cessation: the role of pre- cessation therapy Exp Clin Psychopharmacol 1998; 6: 331–343

    Article  CAS  Google Scholar 

  15. Rose J, Behm F, Westman E . Brand-switching and gender effects in mecamylamine/nicotine smoking cessation treatment In: 5th Annual Meeting of the Society for Research on Nicotine and Tobacco; 1999 March, 1999 San Diego, US: Society for Research on Nicotine and Tobacco 1999

  16. Newman MB et al. Corticosterone-attenutating and anxiolytic properties of mecamylamine in the rat Neuro-Psychopharmacol Biol Psych 2000; 25: 609–620

    Article  Google Scholar 

  17. Yokota T et al. Nicotine-sensitive paresis Neurology 1992; 42: 382–388

    Article  CAS  Google Scholar 

  18. Newman M et al. Nicotine induced seizures blocked by (±)-mecamylamine and its stereoisomers Life Sci 2001; 69: 2583–2591

    Article  CAS  Google Scholar 

  19. Silver AA et al. Multi-center double blind placebo controlled study of mecamylamine monotherapy for Tourette's disorder J Am Acad Child Adolescent Psych 2001; 40: 1101–1110

    Google Scholar 

  20. Shytle RD, Silver AA, Sanberg PR . Comorbid bipolar disorder in tourette syndrome responds to nicotinic receptor antagonist, mecamylamine (Inversine® Biol Psych 2000; 48: 1028–1031

    Article  CAS  Google Scholar 

  21. Shytle RD et al. Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine Depression Anxiety 2002; (in press)

  22. Shytle R et al. Nicotinic acetylcholine receptors as targets for antidepressants Mol Psych 2002; (in press)

  23. Braddom RL, Johnson EW . Mecamylamine in control of hyperreflexia Arch Phys Med Rehabil 1969; 50: 448–453 passim

    CAS  PubMed  Google Scholar 

  24. Braddom RL, Rocco JF . Autonomic dysreflexia. A survey of current treatment Am J Phys Med Rehabil 1991; 70: 234–241

    Article  CAS  Google Scholar 

  25. Rose JE et al. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone Clin Pharmacol Ther 1994; 56: 86–99

    Article  CAS  Google Scholar 

  26. Tennant FS Jr ., Tarver AL, Rawson RA. Clinical evaluation of mecamylamine for withdrawal from nicotine dependence NIDA Res Monogr 1984; 49: 239–246

    PubMed  Google Scholar 

  27. Tennant FS Jr, Tarver AL . Withdrawal from nicotine dependence using mecamylamine: comparison of three-week and six-week dosage schedules NIDA Res Monogr 1984; 55: 291–297

    PubMed  Google Scholar 

  28. Rose JE, Sampson A, Levin ED, Henningfield JE . Mecamylamine increases nicotine preference and attenuates nicotine discrimination Pharmacol Biochem Behavr 1989; 32: 933–938

    Article  CAS  Google Scholar 

  29. Perkins KA . Smoking cessation in women. Special considerations CNS Drugs 2001; 15: 391–411

    Article  CAS  Google Scholar 

  30. Dale LC et al. Bupropion for smoking cessation: predictors of successful outcome Chest 2001; 119: 1357–1364

    Article  CAS  Google Scholar 

  31. Slemmer JE, Martin BR, Damaj MI . Bupropion is a nicotinic antagonist J Pharmacol Exp Ther 2000; 295: 321–327

    CAS  PubMed  Google Scholar 

  32. Villablanca AC, McDonald JM, Rutledge JC . Smoking and cardiovascular disease Clin Chest Med 2000; 21: 159–172

    Article  CAS  Google Scholar 

  33. Omvik P . How smoking affects blood pressure Blood Press 1996; 5: 71–77

    Article  CAS  Google Scholar 

  34. Fogari R, Zoppi A, Malamani GD, Corradi L . Effects of calcium channel blockers on cardiovascular responses to smoking in normotensive and hypertensive smokers Int J Clin Pharmacol Res 1992; 12: 81–88

    CAS  PubMed  Google Scholar 

  35. Ottesen MM, Worck R, Ibsen H . Captopril does not blunt the sympathoadrenal response to cigarette smoking in normotensive humans Blood Press 1997; 6: 29–34

    Article  CAS  Google Scholar 

  36. Trap-Jensen J, Carlsen JE, Svendsen TL, Christensen NJ . Cardiovascular and adrenergic effects of cigarette smoking during immediate non-selective and selective beta adrenoceptor blockade in humans Eur J Clin Invest 1979; 9: 181–183

    Article  CAS  Google Scholar 

  37. Zevin S, Jacob P 3rd, Benowitz NL . Nicotine-mecamylamine interactions Clin Pharmacol Ther 2000; 68: 58–66

    Article  CAS  Google Scholar 

  38. Craig WY, Palomaki GE, Haddow JE . Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data Br Med J 1989; 298: 784–788

    Article  CAS  Google Scholar 

  39. Augustin J, Beedgen B, Sophr U, Winkel F . The influence of smoking on plasma lipoproteins Inner Med 1982; 9: 104–108

    Google Scholar 

  40. Largue G et al. Nicotine gum and the lipid profile Patholog Biol 1989; 37: 937–941

    Google Scholar 

  41. Burch EA Jr, Kadowitz PJ, Kother Copes SMC, Namara DB Jr . The effect of alcoholism and smoking on platelet eicosanoid production in vitro, prostaglandins, leukotrienes essential Fatty Acids 1991; 42: 39–44

    Article  CAS  Google Scholar 

  42. Booyse FM, Osikowicz G, Qarfoot AJ . Effect of Chronic Oral Consumption of Nicotine on the Rabbit Aortic Endothelium Am J Pathol 1981; 102: 229–238

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Cluette-Brown J et al. Oral nicotine induces an atherogenic lipoprotein profile Proc Soc Exp Biol Med 1986; 182: 409–413

    Article  CAS  Google Scholar 

  44. Kavitharaj NK, Vijayammal PL . Nicotine Administration induced changes in the gonadal functions in male rats Pharmacology 1999; 58: 2–7

    Article  CAS  Google Scholar 

  45. Smith TH, Rossi GV . The effect of reserpine and mecamylamine on experimental atheromatosis in the normotensive and hypertensive rat J Pharmacol Exp Ther 1962; 135: 367–373

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Center for Aging and Brain Repair, University of South Florida College of Medicine, Tampa, FL, USA

    R D Shytle & P R Sanberg

  2. Department of Pharmacology, Center for Aging and Brain Repair, University of South Florida College of Medicine, Tampa, FL, USA

    R D Shytle & P R Sanberg

  3. Department of Neurology, Center for Aging and Brain Repair, University of South Florida College of Medicine, Tampa, FL, USA

    P R Sanberg

  4. Department of Psychiatry and Behavioral Medicine, Center for Aging and Brain Repair, University of South Florida College of Medicine, Tampa, FL, USA

    R D Shytle, A A Silver, J Goldman & P R Sanberg

  5. Center for Aging and Brain Repair, Neuroscience Program, University of South Florida College of Medicine, Tampa, FL, USA

    R D Shytle & P R Sanberg

  6. Tampa Division, Layton Bioscience, FL, USA

    E Penny

Authors
  1. R D Shytle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Penny
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A A Silver
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P R Sanberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R D Shytle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shytle, R., Penny, E., Silver, A. et al. Mecamylamine (Inversine®): an old antihypertensive with new research directions. J Hum Hypertens 16, 453–457 (2002). https://doi.org/10.1038/sj.jhh.1001416

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001416

Keywords

This article is cited by

Search

Advanced search

Quick links